SecBot SecBot
SECBOTREPLAY Home › Report › PRAX

PRAX · Praxis Precision Medicines announced a 3-month FDA extension of the…

Praxis Precision Medicines, Inc. · 8-K filed Jun 29, 2026 at 16:40 ET

At the news

BEARISHIMPACT 6/10

8-K filed Jun 29, 2026 at 16:40 ET

Praxis Precision Medicines announced a 3-month FDA extension of the PDUFA target action date for its relutrigine NDA (SCN2A/SCN8A DEEs) from September 27, 2026 to December 27, 2026, following the submission of additional sensitivity analyses deemed a major amendment. No new clinical studies were requested and no safety or manufacturing concerns were cited, but the delay introduces near-term uncertainty for the company's lead pipeline asset.

  • FDA extended PDUFA target action date for relutrigine NDA by 3 months to December 27, 2026
  • Extension triggered by submission of additional sensitivity analyses of existing clinical data, classified as a major amendment
  • No new clinical studies were requested and no safety or manufacturing concerns were cited
  • Review remains active and ongoing; company continues preparations for launch

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access